复宏汉霖携手Sandoz布局生物类似药 首批3款产品落地

财中社
Aug 17

8月17日,复宏汉霖(02696)发布公告,公司于2026年8月16日与Sandoz AG达成战略合作框架协议,预计2026年可实现的开票金额总计不超过1.01亿元美元。此次合作开发最多10款单抗和/或ADC生物类似药相关产品,后续针对各个产品另行签订附属协议确定具体合作条款。  根据协议,Sandoz将向公司支付首付款合计不超过7700万元美元,以及相关产品的开发里程碑款项和销售里程碑款项,合计...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10